Comprehensive evaluation of canine renal papillary necrosis induced by nefiracetam, a neurotransmission enhancer

European Journal of Pharmacology

Volumn 475, Issue 1-3, 2003, Pages 119-128

  Tsuchiya, Yoshimi ^a,b   Takahashi, Yuji ^a   Jindo, Toshimasa ^a   Furuhama, Kazuhisa ^a   Suzuki, Kazuo T ^b  

^a DAIICHI SANKYO CO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Biomarker; Metabolite; Nefiracetam; Prostaglandin; Renal papillary necrosis

Indexed keywords

5 ACETAMIDO 2 (2 METHOXYETHOXY)ACETOPHENONE; 6 OXOPROSTAGLANDIN F1 ALPHA; DRUG METABOLITE; LACTATE DEHYDROGENASE; NEFIRACETAM; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG PENETRATION; EVALUATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY EPITHELIUM; KIDNEY MEDULLA; KIDNEY PAPILLA; KIDNEY PAPILLA NECROSIS; KIDNEY SLICE; MALE; METABOLITE; MONKEY; MORPHOLOGY; NEUROTRANSMISSION; NONHUMAN; OSMOTIC PRESSURE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN URINE LEVEL; RAT; SPECIES COMPARISON; TOXICOKINETICS; URINE OSMOLALITY; URINE VOLUME;

EID: 0041880679     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02123-X     Document Type: Article

References (31)

1. Aihara H., Li X., Fujiwara S., Matsumura T., Okumura S., Tozaki H., Kanno T., Ohta K., Nagai K., Nishizaki T. The protective action of nefiracetam against electrophysiological and metabolic damage in the hippocampus after deprivation of glucose and oxygen. Brain Res. 922:2001;158-162.
2. Alden C.L., Frith C.H. Urinary system. Haschek W.M., Rousseaux C.G. Handbook of Toxicologic Pathology. 1991;347-348 Academic Press, New York, NY.
3. Bach P.H., Hardy T.L. Relevance of animal models to analgesic-associated renal papillary necrosis in humans. Kidney Int. 28:1985;605-613.
4. Bach P.H., Thanh N.T.K. Renal papillary necrosis - 40 years on. Toxicol. Pathol. 26:1998;73-91.
5. Bach P.H., Scholey D.J., Delacruz L., Moret M., Nichol S. Renal and urinary lipid changes associated with an acutely induced renal papillary necrosis in rats. Food Chem. Toxicol. 29:1991;211-219.
6. Clemo F.A.S. Urinary enzyme evaluation of nephrotoxicity in the dog. Toxicol. Pathol. 26:1998;29-32.
7. Endoh H. Biochemistry in nephron - distribution and measurement of enzymes in nephron. Mod. Urin. 3:1987;20-23.
8. Hildebland M., Rinke G., Schlüter G., Bomhard E., Falkenberg F.W. Urinary antigens as markers of papillary toxicity. II: application of monoclonal antibodies for the determination of papillary antigens in rat urine. Arch. Toxicol. 73:1999;233-245.
9. Hooks W.N., Burford P., Begg S., Gopinath C., Inage F., Kato M., Takayama S. Fifty-two-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs. Arzneimittelforschung. 44:1994;228-238.
10. Jindo T., Shimizu Y., Kato M., Takayama S. Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in rats. Arzneimittelforschung. 44:1994;214-216.
11. Kashida Y., Yoshida M., Ishii Y., Nomura M., Kato M. Examination of lesions in the urinary bladder and kidney of dogs induced by nefiracetam, a new nootropic agent. Toxicol. Pathol. 24:1996;549-557.
12. Khan K.N.M., Venturini C.M., Bunch R.T., Brassard J.A., Koki A.T., Morris D.L., Trump B.F., Maziasz T.J., Alden C.L. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol. Pathol. 25:1998;612-620.
13. Kolaja G.J., Packwood W.H., Bell R.R., Ratke C.C., Stout C.L. Renal papillary necrosis and urinary protein alterations induced in Fischer-344 rats by D-ormaplatin. Toxicol. Pathol. 22:1994;29-38.
14. Leibbrandt M.E.I., Wolfgang G.H.I. Differential toxicity of cisplatin, carboplatin, and Cl-973 correlates with cellular platinum levels in rat renal cortical slices. Toxicol. Appl. Pharmacol. 132:1995;245-252.
15. Lupp A., Danz M., Müller D. Morphology and cytochrome P450 isoforms expression in precision-cut rat liver slices. Toxicology. 161:2001;53-66.
16. Miyatake M., Rich K.A., Ingram M., Yamamoto T., Bing R.J. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension. 39:2002;785-789.
17. Molland E.A. Experimental renal papillary necrosis. Kidney Int. 13:1978;5-14.
18. Nabeshima T., Tohyama K., Murase K., Ishihara S., Kameyama T., Yamasaki T., Hatanaka S., Kojima H. Effects of DM-9384, a cyclic derivative of GABA, on cycloheximide-induced amnesia GABAergic and cholinergic neuronal dysfunction. J. Pharmacol. Exp. Ther. 257:1991;271-275.
19. Nishizaki T., Matsuoka T., Nomura T., Sumikawa K., Shiotani T., Watabe S., Yoshii M. Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol. Pharmacol. 53:1998;1-5.
20. Rocha G.M., Michea L.F., Peters E.M., Kirby M., Xu Y., Ferguson D.R., Burg M.B. Direct toxicity of nonsteroidal anti-inflammatory drugs for renal medullary cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5317-5322.
21. Ross B.D., Guder W.G. Heterogeneity and compartmentation in the kidney. Sies H. Metabolic Compartmentation. 1982;363-409 Academic Press, New York, NY.
22. Sabatini S. The pathophysiology of experimentally induced renal papillary necrosis. Semin. Nephrol. 4:1984;27-38.
23. Sabatini S. Analgesic-induced papillary necrosis. Semin. Nephrol. 8:1988;41-54.
24. Sudo K., Hashimoto K., Fujimaki Y., Tachizawa H. Disposition and metabolism of nefiracetam, a new nootropic agent, in the rat, dog and monkey. Jpn. Pharmacol. Ther. 22:1994;81-92.
25. Sugawara T., Kato M., Furuhama K., Inage F., Suzuki N., Akahane K., Takayama S. Thirteen-week oral toxicity study of the new cognition-enhancing agent nefiracetam in dogs. Arzneimittelforschung. 44:1994;217-219.
26. Sugawara T., Kato M., Furuhama K., Inage F., Suzuki N., Takayama S. Single dose toxicity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs. Arzneimittelforschung. 44:1994;211-213.
27. Thanh N.T.K., Obatomi D.K., Bach P.H. Increased urinary uronic acid excretion in experimentally-induced renal papillary necrosis in rats. Ren. Fail. 23:2001;31-42.
28. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 106:1999;13S-24S.
29. Whiting P.H., Tisocki K., Hawksworth G.M. Human renal medullary interstitial cells and analgesic nephropathy. Ren. Fail. 21:1999;387-392.
30. William M., Williaml H., Jeffrey S.S. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am. J. Kidney Dis. 28:1996;S56-S62.
31. Yoshii M., Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells. Brain Res. 642:1994;123-131.